<DOC>
	<DOCNO>NCT00567307</DOCNO>
	<brief_summary>The purpose pilot study provide data feasibility conduct large clinical trial polypill ( combination aspirin , angiotensin convert enzyme inhibitor , thiazide diuretic , statin ) primary prevention cardiovascular disease ( CVD ) . We hypothesize A `` polypill '' comprise aforementioned four component would significantly reduce estimate 10-year total CVD risk score high adherence significant increase adverse effect compare standard practice .</brief_summary>
	<brief_title>Polypill For Prevention Cardiovascular Disease</brief_title>
	<detailed_description>This open-label , parallel-group , randomized clinical trial compare Polypill Standard Practice ( define usual care administer patient similar condition ) . Approximately 200 participant recruit three site Sri Lanka : The National Hospital Sri Lanka , Colombo ; Teaching Hospital , Kegalle , Teaching Hospital , Kandy . Subsequent grant write informed consent , patient undergo screen baseline evaluation confirm eligibility , follow randomization Polypill Standard Practice study arm . Patients receive either intervention return total three monthly clinic visit . Physician acceptability evaluate five-question survey mail random sample physician participate clinical site Council General Practitioners Sri Lanka . Patient acceptability measure participant complete study well screen eligible</detailed_description>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<criteria>Estimated 10year total CVD risk score &gt; 20 % . The total CVD risk assessment base recently develop WHO CVD risk prediction chart No contraindication treatment aspirin , angiotensin convert enzyme inhibitor , lowdose diuretic , statin Informed consent give Patients establish angina pectoris , coronary heart disease , myocardial infarction , transient ischemic attack , stroke , peripheral vascular disease , coronary revascularization and/or carotid endarterectomy Left ventricular hypertrophy ( ECG ) hypertensive retinopathy ( grade III IV ) Patients secondary hypertension Patients diabetes type 1 2 overt neuropathy significant renal disease . Known renal failure impairment Atrial fibrillation ALT &gt; 1.5 time upper limit normal History liver cirrhosis hepatitis History recent gastrointestinal bleeding ( within last year ) Women child bearing period History lifelimiting diseases event Unwillingness sign inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2009</verification_date>
</DOC>